PHI with Early myoclonic encephalopathy

How does this condition affect your private health insurance?

Frühe myoklonische Enzephalopathie (EME) is a rare, severe epileptic encephalopathy of infancy, typically manifesting in the neonatal period. It is characterized by fragmental and erratic myoclonus, often accompanied by focal tonic seizures. The electroencephalogram (EEG) classically shows a burst-suppression pattern. EME is associated with profound psychomotor developmental delay and a poor prognosis. It is frequently caused by underlying genetic or metabolic disorders, such as nonketotic hyperglycinemia or various mitochondrial diseases. Treatment is challenging, focusing on seizure control with anticonvulsants, although often refractory, and supportive care, but the neurodevelopmental outcome remains very poor.

PKV Risk Assessment

Very High Risk of Rejection

Individual, specialized PHI providers may still insure you, but with a significant surcharge.

Impact on Your Insurance Policy

Duration of Illness (Initial)

Days to weeks for initial presentation and diagnosis; symptoms are ongoing.

Duration of Illness (Lifetime)

Chronic and lifelong, often leading to early childhood death.

Cost of Treatment (Initial)

Very high (e.g., tens of thousands to hundreds of thousands of USD for initial hospitalization, diagnostics, and intensive care).

Cost of Treatment (Lifetime)

Very high (e.g., hundreds of thousands to millions of USD for lifelong medication, therapies, and specialized care).

Mortality Rate

High (significant mortality in infancy or early childhood, often exceeding 50% within the first few years of life).

Risk of Secondary Damages

Very high (profound neurodevelopmental delay, intellectual disability, severe motor impairment, and often cerebral palsy are inherent to the disease).

Probability of Full Recovery

Extremely low (virtually 0%; complete recovery without significant neurological sequelae is not expected).

Underlying Disease Risk

High (often associated with underlying genetic metabolic disorders, mitochondrial diseases, or structural brain abnormalities).

The information provided is for general informational purposes only and is not a substitute for professional medical or insurance advice. Always consult with a qualified professional for any health concerns or before making any insurance decisions.